Warning Letter (FDA)
An official FDA communication identifying significant regulatory violations and requesting corrective action. In the peptide space, warning letters have been issued for unapproved therapeutic claims, compounding quality violations, and selling peptide products with drug claims. Warning letters are public documents.
Technical Context
Warning letters in the peptide space have targeted: companies marketing research peptides with therapeutic claims (e.g. advertising BPC-157 or thymosin alpha-1 for specific diseases), compounding pharmacies with quality violations (insanitary conditions, inadequate testing, use of unapproved bulk drug substances), supplement companies selling peptide products with drug claims, and websites selling prescription peptide drugs without valid prescriptions. Warning letter process: FDA issues the letter identifying specific violations → company has 15 business days to respond with corrective action plan → if corrective actions are inadequate, FDA may escalate to enforcement (injunction, seizure, prosecution). Warning letters are published on the FDA's website and searchable through the FDA warning letter database. PeptideTrace tracks these as enforcement events because they signal regulatory positions on specific compounds and industry practices.